John P. Butler

Filings by John P. Butler span 2 companies, the busiest being Akebia Therapeutics, Inc. and Zynerba Pharmaceuticals, Inc. Between 15 January 2016 and 6 August 2026, the trades on record add up to 19 filings.

Market trades split into 1 purchase (€75k) and 7 sales (€367k). On balance, insiders were net sellers of €292k. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Outside the open market, there are 7 share grants and 2 option exercises. 2026 to date brings 1 purchase and 1 sale.

The newest entry dates from 10 August 2026: an option exercise of €191k, in Akebia Therapeutics, Inc. The latest purchase dates back some time: it was published 227 days ago, on 5 March 2026. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. Section 16 rules allow two business days to file each Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.